|
No diabetes (N = 544)
|
Diabetes (N = 219)
|
p value
|
---|
Age (years)
|
65.4 ± 9.7
|
66.4 ± 9.7
|
0.24
|
Male
|
74.8% (407)
|
63.9% (140)
|
0.003
|
BMI (kg/m2)
|
26.8 ± 4.5
|
28.6 ± 5.0
|
<0.0001
|
Smoking (current or past)
|
47.8% (260)
|
47.0% (103)
|
0.85
|
Hypertension
|
67.5% (367)
|
81.3% (178)
|
<0.0001
|
Dyslipidemia
|
61.4% (334)
|
79.5% (174)
|
<0.0001
|
Family history of CAD
|
26.1% (142)
|
22.4% (49)
|
0.28
|
Renal dysfunction (eGFR < 60 ml/min)
|
8.6% (47)
|
12.3% (27)
|
0.12
|
Prior MI
|
24.1% (131)
|
30.6% (67)
|
0.06
|
Prior PCI
|
14.0% (76)
|
17.4% (38)
|
0.24
|
Peripheral vascular disease
|
3.7% (20)
|
6.4% (14)
|
0.10
|
Clinical presentation
| | |
0.37
|
Stable
|
79.2% (431)
|
76.3% (167)
| |
ACS
|
20.8% (113)
|
23.7% (52)
| |
Unstable Angina
|
9.2% (50)
|
15.5% (34)
| |
NSTEMI
|
10.7% (58)
|
6.8% (15)
| |
STEMI
|
0.9% (5)
|
1.4% (3)
| |
Coronary vessel
| | |
0.86
|
Left main
|
3.1% (17)
|
3.7% (8)
| |
LAD
|
60.7% (330)
|
59.4% (130)
| |
LCx
|
17.5% (95)
|
19.6% (43)
| |
RCA
|
18.8% (102)
|
17.4% (38)
| |
Contrast medium
| | |
0.03
|
Iobitridol
|
5.3% (29)
|
5.0% (11)
| |
Iodixanol
|
24.3% (132)
|
26.0% (57)
| |
Iohexol
|
15.8% (86)
|
9.1% (20)
| |
Iomeprol
|
31.1% (169)
|
26.5% (58)
| |
Iopamidol
|
1.3% (7)
|
0.5% (1)
| |
Iopromide
|
7.9% (43)
|
11.9% (26)
| |
Ioversol
|
8.5% (46)
|
10.0% (22)
| |
Ioxaglate
|
5.9% (32)
|
11.0% (24)
| |
Volume of IC contrast (ml)
|
7.9 ± 1.5
|
7.7 ± 1.6
|
0.03
|
5
|
2.0% (11)
|
2.7% (6)
| |
6–7
|
39.7% (216)
|
49.3% (108)
| |
8–9
|
30.1% (164)
|
21.0% (46)
| |
10
|
27.9% (152)
|
26.9% (59)
| |
12
|
0.2% (1)
|
0% (0)
| |
Dose of IC adenosine* (μg)
|
166.3 ± 46.1
|
171.2 ± 47.1
|
0.27
|
<80
|
2.3% (9)
|
1.3% (2)
| |
80–90
|
7.1% (28)
|
7.1% (11)
| |
100–150
|
28.4% (112)
|
29.0% (45)
| |
160–200
|
48.5% (191)
|
45.2% (70)
| |
>200
|
13.7% (54)
|
17.4% (27)
| |
-
ACS acute coronary syndrome, BMI body mass index, CAD coronary artery disease, GFR glomerular filtration rate, IC intracoronary, LAD left anterior descending coronary artery, LCx left circumflex coronary artery, MI myocardial infarction, NSTEMI non ST-segment elevation MI, PCI percutaneous coronary intervention, RCA right coronary artery, STEMI ST-segment elevation MI
- * Only 549 of 763 patients received IC adenosine, while all other rows are based on 763 total